The regulations provide guidance to employers and sponsors regarding the definition of a grandfathered health plan, as well as the changes that may and may not be made.
In June, the Departments of Health and Human Services, Labor and Treasury jointly issued interim final rules providing guidance on grandfathered health plans under the Patient Protection and Affordable Care Act, as modified by the Health Care and Education Reconciliation Act. The regulations provide guidance to employers and sponsors regarding the definition of a grandfathered health plan, as well as the changes that may and may not be made.
Specifically, (among other exemptions) grandfathered health plans: do not have to maintain an appeals process that includes an external review; are not subject to the requirements to provide specified preventive care without any cost sharing to participants; and are not subject to certain nondiscrimination rules.
The interim rules specify a number of changes which would result in the grandfathered health plan losing its status. These include, but are not limited to: entering into a new policy, certificate, or contract of insurance with the plan's insurance issuer; changing the plan to eliminate all or substantially all benefits to diagnose or treat a particular condition; increasing any percentage cost-sharing requirement; and increasing a fixed-amount cost-sharing requirement, other than a copayment (a deductible, for example), if the total percentage increase in the cost-sharing requirement exceeds the "maximum percentage increase."
Changes that will not cause a health plan to lose its grandfather status include: changes to comply with federal or state law; changes to increase benefits; and changes to a plan's third party administrator.
Medicare Patients with PAH Face High Out-of-Pocket Costs | 2024 ATS
May 19th 2024Medicare patients who have pulmonary arterial hypertension and who are eligible for the low-income subsidy often have advanced disease, require prolonged disability insurance and face financial hardships, according to a poster at the annual ATS meeting.
Read More
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More